-
recognize giant cell arteritis (GCA) and list the investigations required for diagnosis.
-
explain the mechanism of action of the interleukin-6 receptor (IL-6R) inhibitor tocilizumab and its biosimilars.
-
explain the role of the IL-6R inhibitor tocilizumab and its biosimilars in the management of GCA, while enumerating co-morbid risk factors and co-medications.
-
summarize the appropriate monitoring of patients with GCA.
About This Course
This course has been designed to provide doctors and other relevant healthcare professionals with a practical overview of the management of giant cell arteritis with interleukin-6 receptor inhibition therapy, with a specific focus on tocilizumab and its biosimilars. This course should take approximately 60 minutes to complete.
This course has a 2-year expiry date of 29th July, 2026. If you complete this course after its expiry date, please double check all claims in this course with up-to-date, peer-reviewed information, as the diagnostic or treatment landscape may have changed.
CME/CPD Information
This course has been accredited by the European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) with 1 European CME credit (ECMEC®). This accreditation certifies the quality and relevance of the educational content.
Learning Outcomes
By the end of this course, you should be able to:
Expert Faculty
This course has been made in close collaboration with:
Course curriculum
-
-
Welcome to the Course
-
-
-
Introduction to Precourse Quiz
-
Precourse Quiz
-
-
-
What is Giant Cell Arteritis?
-
-
-
Diagnosis of Giant Cell Arteritis
-
-
-
General Treatment of Giant Cell Arteritis
-
-
-
Interleukin-6 Receptor Inhibition in GCA
-
-
-
How to Monitor Patients with Giant Cell Arteritis
-
-
-
Introduction to Final Quiz
-
Final Quiz
-
-
-
Conclusions and Take-Home Messages
-
Course Feedback Survey
-
Funding
-
About this course
- Free
- 13 lessons
- 0 hours of video content